Business Context and Reporting Period
This Form 8-K Current Report, dated January 2, 2022, details a material definitive agreement entered into by Allarity Therapeutics, Inc. (the "Company"). The filing reports on an Assignment and Assumption Agreement executed on January 2, 2022, following the Company's acquisition of substantially all assets and liabilities of Allarity Therapeutics A/S ("Allarity A/S") in December 2021.
Key Financial Metrics and Agreement Terms
The filing does not provide current revenue, profit, cash flow, or debt metrics. Instead, it outlines the financial structure of exclusive license agreements with Oncoheroes Biosciences, Inc. ("Oncoheroes") regarding the therapeutic candidates Dovitinib and Stenoparib for pediatric cancers.
- Upfront Fees: The Company will receive upfront license fees and regulatory milestones for each program (specific amounts not disclosed in this text).
- Development Milestones: The Company is entitled to up to $2 million in milestone payments per program upon regulatory approval in the United States and the European Union.
- Royalties: Oncoheroes will pay royalties on annual net sales ranging from 3% to 13%, tiered based on sales volume:
- 3% to 8% on sales between $0 and $100 million.
- 6% to 11% on sales between $100 million and $200 million.
- 8% to 13% on sales in excess of $200 million.
- Commercialization Rights: Oncoheroes acquires exclusive global development and commercialization rights for pediatric cancers, subject to the Company's first buy-back option.
Material Changes and Strategic Shift
The primary material change is the transfer of pediatric cancer development and commercialization rights for Dovitinib and Stenoparib from Allarity A/S to the Company, and subsequently licensed to Oncoheroes. This agreement shifts the responsibility for further clinical development in the pediatric field to Oncoheroes while retaining potential future revenue streams for the Company through milestones and royalties.
Outlook, Risks, and Contingencies
Outlook: The Company anticipates receiving milestone payments and royalties contingent upon Oncoheroes achieving regulatory approvals and commercial sales. The agreements include a buy-back option for the Company to re-acquire pediatric field rights.
Risks and Contingencies:
- Termination: Oncoheroes may terminate the agreements for any reason after the first anniversary with 90 days' notice (pre-commercial sale) or 180 days' notice (post-commercial sale). The Company may terminate if Oncoheroes challenges licensed patents.
- Patent Expiration: Royalty terms are subject to patent validity and may expire on the 15th anniversary of the first commercial sale.
- Forward-Looking Statements: The filing includes standard disclaimers that future results may differ materially from expectations due to risks outside the Company's control.
Investor Verification Checklist
- Verify the specific amounts of the upfront license fees and regulatory milestones, as these figures are not explicitly stated in this 8-K summary.
- Review the full text of the License Agreements (filed as exhibits to the Form 10-K) for detailed definitions of "net sales" and royalty calculation methodologies.
- Assess the status of the "Recapitalization Share Exchange" and the integration of Allarity A/S assets to understand the Company's current balance sheet position.
- Monitor Oncoheroes' clinical development progress for Dovitinib and Stenoparib in pediatric cancers to gauge the likelihood of milestone triggers.
- Confirm the Company's intent and financial capacity to exercise the buy-back option if Oncoheroes terminates the agreement or fails to meet development goals.